NICE, the health technology assessment body for England, says that GW Pharmaceuticals’ cannabidiol product Epidyolex together with clobazam is not recommended for use on the National Health Service for patients with treatment-resistant epilepsy.
NICE said it accepted that cannabidiol plus clobazam was a “promising treatment” for seizures associated with Dravet or Lennox-Gastaut syndrome....








